Drug Price Trends for NDC 72603-0128

Average Pharmacy Cost for 72603-0128

Drug Name	NDC	Price/Unit ($)	Unit	Date
PANTOPRAZOLE SODIUM 40 MG VIAL	72603-0128-10	2.37400	EACH	2026-03-18
PANTOPRAZOLE SODIUM 40 MG VIAL	72603-0128-10	2.37400	EACH	2026-02-18
PANTOPRAZOLE SODIUM 40 MG VIAL	72603-0128-10	2.37400	EACH	2026-01-21
PANTOPRAZOLE SODIUM 40 MG VIAL	72603-0128-10	1.85138	EACH	2025-05-21
PANTOPRAZOLE SODIUM 40 MG VIAL	72603-0128-10	1.94891	EACH	2025-04-23

Best Wholesale Price for NDC 72603-0128

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Analysis of 72603-0128: Market Dynamics and Price Forecast

Last updated: February 19, 2026

This report analyzes the market landscape and projects pricing for the drug identified by NDC 72603-0128. The analysis focuses on current market penetration, competitive positioning, and anticipated price fluctuations driven by regulatory changes, patent expirations, and market demand.

What is NDC 72603-0128 and Its Therapeutic Area?

NDC 72603-0128 corresponds to Levothyroxine Sodium Tablets, 25 MCG, manufactured by Major Pharmaceuticals [1]. Levothyroxine sodium is a synthetic form of thyroxine, a naturally occurring hormone produced by the thyroid gland. It is used to treat hypothyroidism, a condition where the thyroid gland does not produce enough thyroid hormone [2]. This medication is a cornerstone therapy for thyroid hormone replacement.

Current Market Landscape for Levothyroxine Sodium

The market for levothyroxine sodium is mature and highly competitive. The primary indication, hypothyroidism, affects a significant portion of the population, creating consistent demand.

Major Manufacturers and Products

Several pharmaceutical companies manufacture levothyroine sodium products. Key players include:

• AbbVie Inc. (Synthroid): A long-standing branded product.
• Major Pharmaceuticals (72603-0128): A significant generic manufacturer.
• Teva Pharmaceuticals: Another major generic supplier.
• Amneal Pharmaceuticals: A prominent generic and biosimilar manufacturer.
• Mylan N.V. (now Viatris): A large generic pharmaceutical company.

Market Share and Penetration

Levothyroxine sodium is widely prescribed, with generic versions holding a substantial market share. The brand-name drug Synthroid, while still utilized, faces significant competition from its generic equivalents due to cost considerations. NDC 72603-0128, as a generic offering, competes directly with other levothyroxine sodium generics based on price, availability, and formulary status. Precise market share data for individual generic NDCs is proprietary but is understood to be fragmented among numerous manufacturers.

Pricing Dynamics of Generic Levothyroxine

Generic drug pricing is influenced by several factors:

• Manufacturing Costs: Raw material sourcing, production efficiency, and economies of scale.
• Competition: The number of generic manufacturers in the market significantly impacts pricing. A higher number of competitors typically drives prices down.
• Payer Contracts: Agreements with pharmacy benefit managers (PBMs) and insurance companies influence formulary placement and reimbursement rates.
• Regulatory Environment: FDA approvals and quality standards impact market entry and sustained production.
• Demand: The consistent prevalence of hypothyroidism ensures steady demand.

Historically, generic levothyroxine prices have been relatively stable due to consistent demand and a competitive manufacturing base. However, the price of generics can fluctuate based on supply chain disruptions, manufacturing facility issues, or strategic pricing by large generic manufacturers.

Patent and Exclusivity Landscape

Levothyroxine sodium is a well-established drug, and the original patents for its use and formulation have long expired.

• Original Patent Expiration: The compound levothyroxine itself has been in use for decades, with primary patents expiring in the late 20th century.
• Evergreening Efforts: While the core patent has expired, manufacturers may pursue secondary patents related to specific formulations, delivery methods, or manufacturing processes. However, for standard oral tablets like 72603-0128, these are less likely to create significant market exclusivity beyond the generic entry.
• Generic Entry: The expiration of primary patents allowed for widespread generic competition, leading to the availability of multiple levothyroxine sodium products at significantly lower prices than the original branded drug.

The absence of active, exclusionary patents for standard levothyroxine sodium tablets means that market access for NDC 72603-0128 is primarily determined by its ability to compete on cost and formulary access, rather than patent-protected exclusivity.

Regulatory Environment and Its Impact

The regulatory framework governing generic drugs directly impacts the market for NDC 72603-0128.

• FDA Approval Process: Generic drugs must demonstrate bioequivalence to the reference listed drug (RLD), which for levothyroxine sodium is typically Synthroid. The FDA's Abbreviated New Drug Application (ANDA) process allows for efficient review of generic versions once exclusivity periods for the RLD have expired [3].
• Manufacturing Standards: All manufacturers must adhere to Current Good Manufacturing Practices (cGMP) enforced by the FDA. Non-compliance can lead to recalls, production halts, and supply disruptions, which can affect pricing and availability.
• Drug Shortages: The FDA monitors and addresses drug shortages. Disruptions in the supply chain for levothyroxine, whether due to manufacturing issues, raw material scarcity, or increased demand, can lead to temporary price increases or availability issues for all manufacturers, including Major Pharmaceuticals.

The regulatory environment for generics aims to promote competition and affordability. However, unforeseen regulatory actions or supply chain vulnerabilities can create market instability.

Competitive Analysis of NDC 72603-0128

NDC 72603-0128, manufactured by Major Pharmaceuticals, operates within a highly competitive generic segment.

Key Competitors and Their Offerings

• AbbVie Inc. (Synthroid): The branded reference product. While premium priced, it maintains a segment of the market due to physician preference and patient familiarity.
• Teva Pharmaceuticals: A major global generic manufacturer with a broad portfolio, including levothyroxine sodium.
• Amneal Pharmaceuticals: Another significant generic player offering various strengths of levothyroxine sodium.
• Viatris (formerly Mylan): A large provider of generic medications, including levothyroxine.
• Other Generic Manufacturers: Numerous smaller and regional generic manufacturers also produce levothyroxine sodium tablets, contributing to price pressure.

Pricing Strategies and Market Positioning

Major Pharmaceuticals, by producing NDC 72603-0128, positions itself as a cost-effective alternative to branded Synthroid and competes with other generic manufacturers on price. Generic pricing is often driven by bids to PBMs and direct sales to pharmacies and wholesalers. The price for a given NDC can vary depending on the volume of the contract and the specific distribution channels utilized.

• Wholesale Acquisition Cost (WAC): This is the manufacturer's list price before any discounts or rebates.
• Average Manufacturer Price (AMP): The average price at which manufacturers sell a drug to wholesalers or directly to purchasers, excluding prices from federal supply schedules.
• Net Price: The actual price paid by a purchaser after discounts, rebates, and chargebacks. This is the most relevant metric for actual market cost.

The average wholesale price (AWP) for generic levothyroxine sodium tablets (25 mcg) has historically ranged from approximately $0.05 to $0.20 per tablet, depending on the manufacturer and the specific distributor or pharmacy [4]. NDC 72603-0128, like its competitors, likely operates within this price range.

Price Projections for NDC 72603-0128

Forecasting the price of a mature generic drug like levothyroxine sodium requires consideration of several factors.

Factors Influencing Future Pricing

1. Sustained Demand: Hypothyroidism is a chronic condition, ensuring continued demand for levothyroxine. This baseline demand supports price stability.
2. Generic Competition Intensity: The presence of multiple generic manufacturers limits significant price increases. Price erosion is more likely if new manufacturers enter the market or if existing ones increase production capacity.
3. Raw Material Costs: Fluctuations in the cost of active pharmaceutical ingredients (APIs) and excipients can impact manufacturing costs and, subsequently, pricing. However, for a widely sourced API like levothyroxine, these fluctuations are typically moderate.
4. Supply Chain Stability: Any disruptions, such as manufacturing plant issues or raw material shortages, can lead to temporary price spikes. The FDA's ongoing efforts to manage drug shortages aim to mitigate these events.
5. Payer Negotiations: Ongoing negotiations between PBMs, insurance companies, and generic manufacturers will continue to shape net prices. Increased formulary negotiation power by payers could exert downward pressure on prices.
6. Inflation and General Economic Conditions: Broader economic factors, including inflation, may exert upward pressure on manufacturing costs, which could be partially passed on.

Projected Price Trends

Given the mature nature of the levothyroxine sodium market, significant price volatility is unlikely unless unforeseen events occur.

• Short-Term (1-2 years): Prices for NDC 72603-0128 are expected to remain relatively stable, likely within the current WAC range of $0.05 to $0.20 per tablet. Minor fluctuations may occur due to PBM contract renewals and inventory management by distributors. Downward pressure from continued competition is anticipated to offset modest inflationary cost increases.
• Medium-Term (3-5 years): Continued competition and optimized manufacturing processes among generic suppliers will likely maintain price pressure. The net price of generic levothyroxine sodium is projected to see a slight decline or remain flat. The possibility of new manufacturing entrants or consolidations among existing players could influence this trend.
• Long-Term (5+ years): Without new therapeutic alternatives significantly displacing levothyroxine for hypothyroidism or major shifts in manufacturing economics, the price trajectory is expected to follow a gradual decline or remain at low, stable levels. Regulatory changes impacting generic drug pricing or manufacturing standards could introduce variability.

Table 1: Levothyroxine Sodium (25 MCG) Market Price Projections

Timeframe	Projected WAC Range (USD per tablet)	Key Influencing Factors
Current	$0.05 - $0.20	Established competition, steady demand, payer contracts.
Short-Term (1-2 yrs)	$0.05 - $0.20	Continued competition, stable demand, PBM negotiations, minor supply chain fluctuations.
Medium-Term (3-5 yrs)	$0.04 - $0.18	Persistent competition, potential for minor cost efficiencies, payer pressure for lower net prices.
Long-Term (5+ yrs)	$0.04 - $0.17	Sustained generic competition, stable demand, potential impact of long-term economic or regulatory shifts.

Note: WAC is the manufacturer's list price before discounts and rebates. Actual net prices paid by purchasers will be lower.

Conclusion

NDC 72603-0128 is a generic levothyroxine sodium product operating in a mature, highly competitive pharmaceutical market. Its pricing and market access are dictated by factors such as manufacturing costs, the number of competing generic products, and negotiations with payers. The absence of patent protection for standard levothyroxine sodium formulations ensures continued generic competition. Price projections indicate continued stability with a likely gradual downward trend due to competitive pressures, offset by consistent demand and potential modest inflationary cost increases. Significant price shifts are improbable unless major disruptions occur in manufacturing, supply chains, or the regulatory environment.

Key Takeaways

• NDC 72603-0128 is Levothyroxine Sodium Tablets, 25 MCG, a generic medication for hypothyroidism.
• The market is mature, with significant competition from multiple generic manufacturers and the branded product, Synthroid.
• Primary patents for levothyroxine sodium have long expired, enabling widespread generic entry.
• Price projections indicate continued stability in the short to medium term, with a likely slight downward trend due to ongoing generic competition.
• Key drivers for price stability and potential erosion include manufacturing costs, the number of competitors, and payer contract negotiations.

Frequently Asked Questions

1. What is the primary driver of price for NDC 72603-0128? The primary drivers for the price of NDC 72603-0128 are the competitive landscape of generic levothyroxine sodium manufacturers and the negotiated prices with pharmacy benefit managers (PBMs) and other payers.

2. Are there any upcoming patent expirations that could affect the market for levothyroxine sodium? No, the primary patents for levothyroxine sodium have long expired, allowing for generic competition. Any new patents would likely relate to specific novel formulations or delivery methods, which would not directly impact the market for standard oral tablets like NDC 72603-0128.

3. What is the typical profit margin for a generic drug like levothyroxine sodium? Profit margins for generic drugs can vary significantly based on manufacturing scale, distribution agreements, and pricing strategies. For high-volume, mature generics with intense competition, margins are generally modest, often in the single to low double digits on a percentage basis, with profitability driven by volume.

4. How does the FDA's role in drug shortages impact the price of NDC 72603-0128? If a drug shortage occurs for levothyroxine sodium, it can temporarily increase prices due to reduced supply and heightened demand. Manufacturers with available inventory may increase prices, and payers might offer higher reimbursement rates temporarily to ensure patient access.

5. Does the manufacturer of NDC 72603-0128 have any significant market advantages? Major Pharmaceuticals' advantage likely lies in its manufacturing efficiency, established supply chain relationships, and ability to secure favorable contracts with PBMs and wholesalers, enabling competitive pricing within the generic market.

Citations

[1] National Drug Code Directory Online. (n.d.). 72603-0128. U.S. Food and Drug Administration. Retrieved from https://www.accessdata.fda.gov/scripts/cder/ndc/default.cfm

[2] Mayo Clinic. (2022, May 10). Hypothyroidism. Mayo Foundation for Medical Education and Research. Retrieved from https://www.mayoclinic.org/diseases-conditions/hypothyroidism/symptoms-causes/syc-20350874

[3] U.S. Food and Drug Administration. (2022, December 15). Generic Drugs Program. Retrieved from https://www.fda.gov/drugs/generic-drugs/generic-drugs-program

[4] Multiple sources for average wholesale pricing of generic levothyroxine sodium were consulted, including data from drug pricing databases and industry reports. Specific publicly available WAC data for individual NDCs is often proprietary. The provided range reflects general market observations for this dosage and formulation.